]>
IRCT20191111045407N1 IRCT 2019-12-13 Esfahan University of Medical Sciences Citalopram and Pramipexole in depression in Parkinson disease Comparison of Citalopram and Pramipexole treatments on depression in Parkinson disease 2020-01-21 anticipated 44 Complete https://irct.ir/trial/43869 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple Random Samples From a Table of Random Numbers. 2-3 Parkinson disease. Intervention 1: Intervention group 1: Patients receiving citalopram 10 mg daily for the first week and then 20 mg daily. Intervention 2: Intervention group 2: Patients receiving pramipexole 0.09 mg twice a day for the first week and then 0.18 mg twice a day. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information
public Ehsan Ziaei
No. 160, Tayebantayeba Alley, Shahidi Alley, Khaghani St.
Isfahan Iran (Islamic Republic of) 8175844511 +98 31 3620 1286 ziaei@resident.mui.ac.ir Esfahan University of Medical Sciences scientific Ehsan Ziaei
No. 160, Tayebantayeba Alley, Shahidi Alley, Khaghani St.
Isfahan Iran (Islamic Republic of) 8175844511 +98 31 3620 1286 ziaei@resident.mui.ac.ir Esfahan University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Controlled disease with monotheraphy with Levodopa 35 years 80 years Both Cognitive disorders Psychotic disorders and suicidal thought or attempt Use of antipsychotics, anticholinergics, dopamine agonists and other psychological drugs and therapies Use of metoclopramide, methyldopa, methylphenidate, reserpine, flunarizine, Cinnarizine and amphetamine derivatives within the past 3 months History of malignant melanoma History of previous deep brain stimulation surgery Pregnancy Lactating using contraceptive drugs “Off” period for greater than 50% of the day G20 Parkinson's disease Treatment - Drugs Treatment - Drugs Intervention group 1: Patients receiving citalopram 10 mg daily for the first week and then 20 mg daily Intervention group 2: Patients receiving pramipexole 0.09 mg twice a day for the first week and then 0.18 mg twice a day Beck depression inventory total score. Timepoint: Assessment of depression score in Beck depression inventory at baseline (before intervention) and 8 weeks after starting pramipexole or citalopram. Method of measurement: Beck depression inventory. Quality of life score. Timepoint: Assessment of quality of life score with Parkinson's Disease Questionnaire at baseline (before intervention) and 8 weeks after starting pramipexole or citalopram. Method of measurement: Parkinson's Disease Questionnaire. Esfahan University of Medical Sciences Approved 2019-11-02 Ethics committee of Isfahan University of Medical Sciences No. 160, Tayebantayeba alley, Shahidi Alley, Khaghani St. Isfahan Isfehan Iran (Islamic Republic of)